PFE

Pfizer Invites Shareholders to Attend Virtual-Only 2023 Annual Meeting of Shareholders on April 27

Retrieved on: 
Thursday, April 13, 2023
Biotechnology, Finance, Health, Professional Services, Pharmaceutical, Webcast, PFE, Annual Meetings of the International Monetary Fund and the World Bank Group, Inc., Annual general meeting, Pfizer, Conduct, NYSE, EDT, Security (finance)

Guests may participate in a listen-only mode. No control number is required. A replay of the webcast will be available for up to one year at: https://investors.pfizer.com/Investors/Events--Presentations.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual-only 2023 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 27, 2023.
  • Pfizer has designed the virtual Annual Meeting to ensure that its shareholders who attend the virtual-only Annual Meeting will be afforded comparable rights and opportunities to participate as they would at an in-person meeting.
  • Beginning today, shareholders can find additional information on accessing and registering for the virtual meeting at www.meetnow.global/MAGVNLW .
  • Shareholders also may submit questions in advance of the meeting by following the instructions provided on the “Rules of Conduct and Meeting Procedures” available on the virtual meeting platform.

FDA Accepts Pfizer’s Supplemental New Drug Applications for BRAFTOVI + MEKTOVI

Retrieved on: 
Tuesday, April 4, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Inc., CRC, Prescription Drug User Fee Act, PFE, Cancer, BRAF, Mutation, Pfizer, NSCLC, Lung cancer, Cetuximab, Patient, PDUFA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NYSE, Food, Safety, Pharmaceutical industry

Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental New Drug Applications (sNDAs) for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.

Key Points: 
  • Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental New Drug Applications (sNDAs) for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.
  • The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is in Fourth-Quarter 2023 for the sNDAs.
  • In the U.S., BRAFTOVI + MEKTOVI is currently approved for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
  • "Through our comprehensive development program, the BRAFTOVI and MEKTOVI combination has shown the potential to help more patients, such as those living with BRAF V600E-mutant non-small cell lung cancer.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)

Retrieved on: 
Thursday, March 23, 2023
Tripura Merger Agreement, HNI, Brodsky, PFE, CVS, Pfizer, HNI Corporation, Oak Street Health, SNY, NYSE, Security (finance), Seagen, Sanofi

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the deal, Oak Street Health will be acquired by CVS Health® (“CVS”) (NYSE - CVS).
  • Oak Street Health stockholders will receive $39.00 per share in an all-cash transaction, representing an enterprise value of approximately $10.6 billion.
  • Kimball shareholders will receive $9.00 in cash and 0.1301 shares of HNI common stock for each share of Kimball common stock they own.

Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts

Retrieved on: 
Tuesday, March 21, 2023
Biotechnology, Health, Science, Pharmaceutical, Research, Webcast, PFE, Inc., Performance report, Pfizer, NYSE, EDT

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 2, 2023.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 2, 2023.
  • To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors .
  • Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today.
  • You can also listen to the conference call by dialing either 800-456-4352 in the United States and Canada or 785-424-1086 outside of the United States and Canada.

FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™

Retrieved on: 
Thursday, March 16, 2023
Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Cancer, PFE, New Drug Application, Smoking, EPIC, EC, Prescription Drug User Fee Act, Patient, Hospital, U.S. FDA, NYSE, Risk, Obesity, Death, SARS-CoV-2, Senior, EUA, European Commission, COVID-19, Disease, Evaluation, Internal medicine, Safety, CDC, Clinical trial, Vaccination, PDUFA, Omicron, Inc., Food, Diabetes, Rusyns, Ageing, NDA, Virulence, Civil service commission, Pharmaceutical industry, Vaccine, Pfizer

The AMDAC's vote, while not binding, will be considered by the FDA when making its decision regarding the potential approval of PAXLOVID.

Key Points: 
  • The AMDAC's vote, while not binding, will be considered by the FDA when making its decision regarding the potential approval of PAXLOVID.
  • “We are encouraged by the AMDAC’s positive vote today.
  • The data showed an 86% reduction in risk of COVID-19-related hospitalization or death from any cause through Day 28 in patients treated with PAXLOVID within 5 days of symptoms onset, compared to placebo.
  • The target Prescription Drug User Fee Act (PDUFA) action date for a decision by the FDA is May 2023.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qualtrics (Nasdaq - XM), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)

Retrieved on: 
Monday, March 13, 2023
PFE, HNI Corporation, SNY, NYSE, Pfizer, Tripura Merger Agreement, Qualtrics, Brodsky, Silver, HNI, Security (finance), Sanofi, Seagen

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Silver Lake will pay $18.15 in cash for each share of Qualtrics common stock in a deal valued at approximately $12.5 billion.
  • Kimball shareholders will receive $9.00 in cash and 0.1301 shares of HNI common stock for each share of Kimball common stock they own.
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

SEAGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Seagen Inc. - SGEN

Retrieved on: 
Monday, March 13, 2023
Class Action Lawsuit, Professional Services, Legal, PFE, Pfizer, KSF, Sale, NYSE, Seagen

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Seagen Inc. (NasdaqGS: SGEN) to Pfizer Inc. (NYSE: PFE).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Seagen Inc. (NasdaqGS: SGEN) to Pfizer Inc. (NYSE: PFE).
  • Under the terms of the proposed transaction, shareholders of Seagen will receive $229 in cash for each share of Seagen that they own.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Pfizer Invests $43 Billion to Battle Cancer

Retrieved on: 
Monday, March 13, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Webcast, Brentuximab vedotin, Neoplasm, Wachtell, Lipton, Rosen & Katz, NYSE, Clinical trial, Breast cancer, Medicine, Oliver Cromwell, Inc., Guggenheim Partners, Prostate cancer, Flushing Avenue station (IND Crosstown Line), Spacecraft, Bone marrow, ADC, PFE, Cancer, Clinical Genitourinary Cancer, Acquisition, Death, Patient, Multimedia, Financial toxicity, Centerview Partners, Immune system, Growth, EDT, FDA, Sullivan & Cromwell, Public, EPS, Hematology, Pharmaceutical industry, Fine chemical, Medical imaging, Pfizer, Seagen

View the full release here: https://www.businesswire.com/news/home/20230313005389/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230313005389/en/
    “Pfizer is deploying its financial resources to advance the battle against cancer, a leading cause of death worldwide with a significant impact on public health,” said Dr. Albert Bourla, Pfizer Chairman and Chief Executive Officer.
  • Pfizer’s in-line portfolio is focused on four broad, key areas: breast cancer, genitourinary cancer, hematology and precision medicine, complemented by an extensive pipeline of 33 programs in clinical development.
  • “Over the past decade we’ve taken bold new approaches to translating scientific research into effective medicines for people living with cancer, and we have pioneered several breakthroughs in breast cancer, genitourinary cancer, hematological malignancies and precision medicine,” said Chris Boshoff, Chief Development Officer Oncology and Rare Disease, Pfizer.
  • Pfizer expects to achieve nearly $1 billion in cost efficiencies in the third full year after the completion of the transaction.

Pfizer Invests $43 Billion to Battle Cancer

Retrieved on: 
Monday, March 13, 2023
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Webcast, Brentuximab vedotin, Neoplasm, Wachtell, Lipton, Rosen & Katz, NYSE, Clinical trial, Breast cancer, Medicine, Oliver Cromwell, Inc., Guggenheim Partners, Prostate cancer, Flushing Avenue station (IND Crosstown Line), Spacecraft, Bone marrow, ADC, PFE, Cancer, Clinical Genitourinary Cancer, Acquisition, Death, Patient, Multimedia, Financial toxicity, Centerview Partners, Immune system, Growth, EDT, FDA, Sullivan & Cromwell, Public, EPS, Hematology, Pharmaceutical industry, Fine chemical, Medical imaging, Pfizer, Seagen

View the full release here: https://www.businesswire.com/news/home/20230313005335/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230313005335/en/
    “Pfizer is deploying its financial resources to advance the battle against cancer, a leading cause of death worldwide with a significant impact on public health,” said Dr. Albert Bourla, Pfizer Chairman and Chief Executive Officer.
  • Pfizer’s in-line portfolio is focused on four broad, key areas: breast cancer, genitourinary cancer, hematology and precision medicine, complemented by an extensive pipeline of 33 programs in clinical development.
  • “Over the past decade we’ve taken bold new approaches to translating scientific research into effective medicines for people living with cancer, and we have pioneered several breakthroughs in breast cancer, genitourinary cancer, hematological malignancies and precision medicine,” said Chris Boshoff, Chief Development Officer Oncology and Rare Disease, Pfizer.
  • Pfizer expects to achieve nearly $1 billion in cost efficiencies in the third full year after the completion of the transaction.

Finastra and Uni Systems extend collaboration to enable financial institutions to meet new risk management regulation

Retrieved on: 
Tuesday, March 14, 2023
Var, BCBS, Software as a service, Basel Committee on Banking Supervision, Azure, Fundamental Review of the Trading Book, Jews and the American Slave Trade, Uni-Systems, Credit risk, PFE, Self-publishing, Capital market, Microsoft Azure, CPO, Potential future exposure, Finastra, Treasury, Microsoft, FRTB, Partnership, CVA, Bank, Cryptocurrency, Risk management, Adriatic Sea

LONDON and ATHENS, Greece, March 14, 2023 /PRNewswire/ -- Finastra and Uni Systems have extended their partnership to help financial institutions in the Adriatic, Central and Southeast Europe regions comply with the Basel Committee's Fundamental Review of the Trading Book (FRTB) reporting requirements, effective in 2025. Under the new agreement, Uni Systems can offer its customers Vector Risk's Trading Book Market & Credit Risk Solution, via Finastra's FusionFabric.cloud and hosted on Microsoft Azure, for cloud-based automation of credit and market risk calculations in the trading book.

Key Points: 
  • Under the new agreement, Uni Systems can offer its customers Vector Risk's Trading Book Market & Credit Risk Solution, via Finastra's FusionFabric.cloud and hosted on Microsoft Azure, for cloud-based automation of credit and market risk calculations in the trading book.
  • The FRTB is a comprehensive suite of rules proposed by the Basel Committee on Banking Supervision (BCBS) that capital banks must hold against market risk exposures.
  • Trading Book Market & Credit Risk is a SaaS solution providing out-of-the-box connectivity with Finastra's treasury and capital market solutions, standard market data packages and institutions' internal data.
  • Uni Systems provides strategic guidance, project management and technical execution.